HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival

Diseases of the Esophagus

Volumn 19, Issue 4, 2006, Pages 224-231

  Dreilich, M ^a   Wanders, A ^a   Brattstrom D ^a   Bergstrom S ^a   Hesselius, P ^a   Wagenius, G ^a   Bergqvist, Michael ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological monitoring; Esophageal carcinoma; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEOPLASM METASTASIS; NEOPLASMS, SQUAMOUS CELL; RADIATION TOLERANCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33745815277     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00570.x     Document Type: Article

References (52)

1. Socialstyrelsen: Cancer incidence in Sweden 2003. Uppsala: National Board of Health and Welfare. Available at: http://www.socialstyrelsen.se/ Publicerat/2004/8636/2004-42-10.htm
2. Incarbone R, Bonavina L, Szachnowicz S, Saino G, Peracchia A. Rising incidence of esophageal adenocarcinoma in Western countries: Is it possible to identify a population at risk? Dis Esophagus 2000; 13: 275-8.
3. Tytgat G N, Bartelink H, Bernards R et al. Cancer of the esophagus and gastric cardia: Recent advances. Dis Esophagus 2004; 17: 10-26.
4. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
5. Alexandrou A, Davis P A, Law S, Murthy S, Whooley B P, Wong J. Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: Similarities and differences. Dis Esophagus 2002; 15: 290-5.
6. Nakamura T, Nekarda H, Hoelscher A H et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994; 73: 1785-94.
7. Lam K Y, Tin L, Ma L. C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 1998; 24: 431-5.
8. Kleeff J, Friess H, Liao Q, Buchler M W. Immunohistochemical presentation in non-malignant and malignant Barrett's epithelium. Dis Esophagus 2002; 15: 10-15.
9. Hynes N E, Stern D F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-84.
10. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-72.
11. Riese D J 2nd, van Raaij T M, Plowman G D, Andrews G C, Stern D F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995; 15: 5770-6.
12. Brattstrom D, Wester K, Bergqvist M et al. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Acta Oncol 2004; 43: 80-6.
13. Ross J S, McKenna B J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19: 554-68.
14. Ross J S, Fletcher J A. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist 1998; 3: 237-52.
15. Salomon D S, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
16. Holbro T, Beerli R R, Maurer F, Koziczak M, Barbas C F 3rd, Hynes N E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8.
17. Oken M M, Creech R H, Tormey D C et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
18. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43.
19. Yarden Y, Sliwkowski M X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
20. Hardwick R H, Barham C P, Ozua P et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997; 23: 30-5.
21. Syrjanen K J. HPV infections and oesophageal cancer. J Clin Pathol 2002; 55: 721-8.
22. Friess H, Fukuda A, Tang W H et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999; 23: 1010-18.
23. Onn A, Correa A M, Gilcrease M et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10: 136-43.
24. Sartor C. Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Semin Oncol 2000; 27: 15-20.
25. Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 664-71.
26. Nishioka T, West C M, Gupta N et al. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol 1999; 125: 96-100.
27. Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H. Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 2003; 13: 849-55.
28. Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003; 57: 1323-7.
29. Zhan M, Han Z C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 2004; 19: 915-23.
30. Sato S, Kajiyama Y, Sugano M et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005; 61: 203-11.
31. Uno M, Otsuki T, Kurebayashi J et al. Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer 2001; 94: 474-9.
32. Dahlberg P S, Jacobson B A, Dahal G et al. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 2004; 78: 1790-800.
33. McKeage K, Perry C M. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62: 209-43.
34. Gupta D, Middleton L P, Whitaker M J, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003; 119: 381-7.
35. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002; 15: 657-65.
36. Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88: 1587-91.
37. Walch A, Specht K, Braselmann H et al. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer 2004; 112: 747-53.
38. Safran H, DiPetrillo T, Nadeem A et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: A phase I study. Cancer Invest 2004; 22: 670-7.
39. Geddert H, Zeriouh M, Wolter M, Heise J W, Gabbert H E, Sarbia M. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002; 118: 60-6.
40. Brien T P, Odze R D, Sheehan C E, McKenna B J, Ross J S. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000; 31: 35-9.
41. Polkowski W, van Sandick J W, Offerhaus G J et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999; 6: 290-7.
42. Persons D L, Croughan W S, Borelli K A, Cherian R. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 1998; 106: 11-17.
43. Duhaylongsod F G, Gottfried M R, Iglehart J D, Vaughn A L, Wolfe W G. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995; 221: 677-83; discussion 683-74.
44. Flejou J F, Paraf F, Muzeau F et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations. J Clin Pathol 1994; 47: 23-6.
45. al-Kasspooles M, Moore J H, Orringer M B, Beer D G. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993; 54: 213-19.
46. Jankowski J, Coghill G, Hopwood D, Wormsley K G. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992; 33: 1033-8.
47. Mimura K, Kono K, Hanawa M et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92: 1253-60.
48. Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004; 91: 666-72.
49. Suzuki H, Abo S, Kitamura M et al. Gene amplification of int-2 and erbB in human esophageal cancer: Relationship to clinicopathological variables. Cancer Invest 1997; 15: 411-15.
50. Ikeda Y, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. Ann Thorac Surg 1996; 62: 835-8.
51. Suo Z, Holm R, Nesland J M. Squamous cell carcinomas, an immunohistochemical and ultrastructural study. Anticancer Res 1992; 12: 2025-31.
52. Suo Z, Su W, Holm R, Nesland J M. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res 1995; 15: 2797-8.